Related Experiment Videos
Huntington's disease like-2: review and update
Russell L Margolis1, Dobrila D Rudnicki, Susan E Holmes
1Laboratory of Genetic Neurobiology, Division of Neurobiology, Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, USA. rmargoli@jhmi.edu
Acta Neurologica Taiwanica
|April 20, 2005
Summary
Huntington's Disease-like 2 (HDL2) is a rare neurodegenerative disorder caused by a CTG/CAG expansion. Despite similarities to Huntington's disease (HD), HDL2 is not a polyglutamine disease and may offer insights into HD pathogenesis.
Area of Science:
- Neuroscience
- Genetics
- Pathology
Background:
- Huntington's Disease-like 2 (HDL2) shares clinical and neuropathological features with Huntington's disease (HD), including adult onset, progressive neurodegeneration, and striatal atrophy.
- HDL2 is rare overall but more prevalent in individuals of African ancestry, approaching HD's frequency in some populations.
- The genetic basis involves a CTG/CAG expansion on chromosome 16q24.3, with repeat length correlating to onset age, similar to HD.
Purpose of the Study:
- To elucidate the genetic and molecular underpinnings of HDL2.
- To investigate the relationship between HDL2 and Huntington's disease (HD).
- To explore potential therapeutic targets by understanding HDL2 pathobiology.
Main Methods:
- Genetic analysis to identify CTG/CAG repeat expansions.
- Comparative analysis of clinical and neuropathological features between HDL2 and HD.
- Molecular studies to investigate the role of Junctophilin-3.
Main Results:
- HDL2 is caused by a CTG/CAG expansion mutation in Junctophilin-3, not a polyglutamine expansion.
- Phenotypic similarities between HDL2 and HD suggest shared pathogenetic mechanisms.
- Repeat length in HDL2 correlates with age of onset, mirroring HD patterns.
Conclusions:
- HDL2, while phenotypically similar to HD, has a distinct molecular basis involving Junctophilin-3.
- Understanding HDL2 pathogenesis may provide novel insights into HD and other striatal neurodegenerative disorders.
- Further research into HDL2 could reveal new therapeutic strategies for neurodegeneration.